Carnosine for Peripheral Arterial Disease

(CAR-PAD Trial)

Age: 18+

Sex: Male

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Recruiting

Sponsor: Shahid Baba

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial tests if taking L-carnosine supplements can help people with PAD improve their leg function and walk more easily by promoting new blood vessel growth and reducing muscle stress. Carnosine is a dipeptide stored in muscle and brain tissue, known for its antioxidant properties and potential benefits in managing peripheral vascular disease.

Research Team

Eligibility Criteria

This trial is for men aged 50-80 with Peripheral Arterial Disease, having an ABI of 0.4 to less than 0.60, and who can follow the study rules. They must be White or African American, speak English, and give informed consent. It's not for those with severe diseases like HIV or cancer, carnosinemia, allergies to L-carnosine/meat, pacemakers/metal implants, recent major injuries/amputations/ulcers or uncontrolled diabetes.

Inclusion Criteria

Your ankle-brachial index (ABI) is between 0.4 and less than 0.60.

Willing to comply with protocol requirements

White or African American race

Exclusion Criteria

You have HIV, hepatitis, severe liver disease, active infection, anemia, organ transplant, kidney disease needing dialysis, lung disease needing oxygen, serious heart disease from birth, any type of cancer, or untreated thyroid disease.

You have been diagnosed with carnosinemia.

You are allergic to L-carnosine or meat.

Treatment Details

Interventions

• Carnosine (Dipeptide)

Trial Overview The trial tests if taking L-carnosine pills helps improve leg function in PAD patients by increasing muscle carnosine levels and promoting new blood vessel growth.

Participant Groups

Group I: Carnosine intervention for patients with PAD Experimental Treatment 1 Intervention

This is a single arm open labelled safety trial, where we will supplement carnosine for 3 months to subjects with non-claudication and claudication peripheral arterial disease (PAD), and determine if it improves walking ability.

Who Is Running the Clinical Trial?

Shahid Baba

Lead Sponsor

Trials

2

Recruited

140+

University of Louisville

Lead Sponsor

Trials

353

Recruited

76,400+